TapewireFind a company

person · Reporting owner

SCHULER JACK W

Disclosed activity across 9 companies

Tapewire entity
23810
SEC CIK
0001021412

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Accelerate Diagnostics, IncAXDX · Entity 78156Director · 10% ownerDecember 03, 2024December 03, 2024
Aspira Women's Health Inc.AWHL · Entity 787110% ownerJune 05, 2026June 09, 2026
BIODESIX INCBDSX · Entity 605310% owner · Emeritus DirectorAugust 12, 2026August 13, 2026
BIOLASE, INCBIOL · Entity 1147010% ownerFebruary 11, 2020May 15, 2020
Neos Therapeutics, Inc.NEOS · Entity 14106110% ownerFebruary 17, 2017February 17, 2017
QUIDEL CORP /DE/QDEL · Entity 126712Director · 10% ownerMay 14, 2020May 18, 2020
STERICYCLE INCSRCL · Entity 80873DirectorApril 30, 2018May 02, 2018
YIELD10 BIOSCIENCE, INC.YTEN · Entity 8819510% ownerDecember 20, 2023May 17, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Accelerate Diagnostics, Inc

Report date December 03, 2024 · Filed December 03, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Jack W. Schuler Living Trust8,310,388 Reported balance After 2024-12-03 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2024-12-03 · Sale · Disposed 200,000 · Balance 8,310,388

F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes.

F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.

Common StockSEC Table I · non-derivativeDirect20,225 Reported balance Holding disclosure · report date 2024-12-03 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 20,225

Common StockSEC Table I · non-derivativeIndirectBy Spouse5,497 Reported balance Holding disclosure · report date 2024-12-03 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 5,497

F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes.

F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.

F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Aspira Women's Health Inc.

Report date June 05, 2026 · Filed June 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Jack W. Schuler Living Trust4,046,051 Reported balance After 2026-06-05 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2026-06-05 · Purchase · Acquired 222,222 · Balance 4,046,051

F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2029-06-05IndirectBy Jack W. Schuler Living Trust300,000 Reported balance After 2026-06-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-06-05 · Purchase · Acquired 300,000 · Balance 300,000

F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-09-17IndirectBy Jack W. Schuler Living Trust833,333 Reported balance Holding disclosure · report date 2026-06-05 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance 833,333

F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2030-03-12IndirectBy Jack W. Schuler Living Trust1,801,265 Reported balance Holding disclosure · report date 2026-06-05 · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · Balance 1,801,265

F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-07-26IndirectBy Jack W. Schuler Living Trust28,500 Reported balance Holding disclosure · report date 2026-06-05 · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · Balance 28,500

F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-01-26IndirectBy Jack W. Schuler Living Trust8,888 Reported balance Holding disclosure · report date 2026-06-05 · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · Balance 8,888

F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

Common StockSEC Table I · non-derivativeDirect6,536 Reported balance Holding disclosure · report date 2026-06-05 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 6,536

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2027-07-09Direct6,536 Reported balance Holding disclosure · report date 2026-06-05 · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · Balance 6,536

Filing footnotes · ownership attribution and instrument terms

F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

BIODESIX INC

Report date August 12, 2026 · Filed August 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Jack W. Schuler Living Trust555,810 Reported balance After 2026-08-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2026-08-12 · Purchase · Acquired 15,000 · Balance 555,810

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Common StockSEC Table I · non-derivativeIndirectBy Jack W. Schuler 2026 GRAT1,800,000 Reported balance Holding disclosure · report date 2026-08-12 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 1,800,000

F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT.

BIOLASE, INC

Report date February 11, 2020 · Filed May 15, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Trust739,820 Reported balance After 2020-02-11 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2020-02-11 · Sale · Disposed 1,307,931 · Balance 739,820

F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018.

F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust.

Common StockSEC Table I · non-derivativeIndirectBy Spouse20,000 Reported balance Holding disclosure · report date 2020-02-11 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 20,000

F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018.

F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust.

Neos Therapeutics, Inc.

Report date February 17, 2017 · Filed February 17, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy the Jack W Schuler Living Trust2,338,671 Reported balance Holding disclosure · report date 2017-02-17 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 2,338,671

F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

QUIDEL CORP /DE/

Report date May 14, 2020 · Filed May 18, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,103,249 Reported balance After 2020-05-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2020-05-14 · Exercise / conversion · Acquired 2,100 · Balance 3,103,249

F1: Reflects release of restricted stock units that were previously reported on Form 4.

F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-05-14 · Exercise / conversion · Disposed 2,100 · Balance 0

F3: Restricted stock units convert into common stock on a one-for-one basis.

F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects release of restricted stock units that were previously reported on Form 4.

F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any.

F3: Restricted stock units convert into common stock on a one-for-one basis.

F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date.

STERICYCLE INC

Report date April 30, 2018 · Filed May 02, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct2,078 Reported balance After 2018-04-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-04-30 · Grant · Acquired 170 · Balance 2,078

F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

YIELD10 BIOSCIENCE, INC.

Report date December 20, 2023 · Filed May 17, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Jack W. Schuler Living Trust63,789 Reported balance After 2023-12-20 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2023-12-20 · Sale · Disposed 36,000 · Balance 63,789

F1: This late filing is due to an inadvertent administrative error.

F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split.

F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Filing footnotes · ownership attribution and instrument terms

F1: This late filing is due to an inadvertent administrative error.

F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split.

F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SOLENO THERAPEUTICS INC

Report date December 09, 2022 · Filed May 15, 2023

Section 16 reporting ended · disclosed 2023-05-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Jack W. Schuler Living Trust36,595 Reported balance After 2022-12-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2022-12-09 · Sale · Disposed 10,000 · Balance 36,595

F1: This late filing is due to an inadvertent administrative error.

F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust.

Filing footnotes · ownership attribution and instrument terms

F1: This late filing is due to an inadvertent administrative error.

F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 07, 2020 Filed Dec 10, 2020 02:42 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 35,157 $6.83 $240,122.31
Disclosure

SEC source: 0000905148-20-001263 · form4.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 5,701,979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F1 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
December 07, 2020 Filed Aug 3, 2021 22:43 UTC SOLENO THERAPEUTICS INC SLNO · Entity 46432 SaleCommon Stock 65,782 $1.91 $125,367.34
Disclosure

SEC source: 0000899243-21-031364 · doc4.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 11,303,080

F1 · ownership.nature: The shares are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 Conversion3% Convertible Debt due June 2021 · Derivative Not disclosed $0.00 Strike: $14.40 $10,586,622.58
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 14

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 0

Underlying: Common Stock · 753,735 shares

Expires 2021-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries H Preferred Stock · Derivative 5,366,411 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 12

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 0

Underlying: Common Stock · 904,060 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries G Preferred Stock · Derivative 9,419,362 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 11

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 0

Underlying: Common Stock · 1,586,846 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries F Preferred Stock · Derivative 6,273,780 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 10

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 0

Underlying: Common Stock · 1,056,921 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries E Preferred Stock · Derivative 1,759,853 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 9

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 0

Underlying: Common Stock · 296,476 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries D Preferred Stock · Derivative 3,101,784 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 8

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 0

Underlying: Common Stock · 522,546 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries C Preferred Stock · Derivative 333,333 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 7

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 0

Underlying: Common Stock · 56,155 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries B-1 Preferred Stock · Derivative 1,250,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 6

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 0

Underlying: Common Stock · 245,041 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers give effect to such conversion. The B-1 Preferred Stock had no expiration date.

F3 · derivative.exercise_date: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers give effect to such conversion. The B-1 Preferred Stock had no expiration date.

F3 · derivative.expiration_date: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers give effect to such conversion. The B-1 Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries B Preferred Stock · Derivative 1,454,545 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 5

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 0

Underlying: Common Stock · 245,042 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 PurchaseCommon Stock 277,777 $18.00 $4,999,986.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · nonDerivative · entry 4

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Schuler Family Foundation

Disclosed balance after: 277,777

F4 · ownership.direct: The Reporting Person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the Reporting Person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the Reporting Person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation.

F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the Reporting Person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the Reporting Person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionCommon Stock 753,735 $14.40 $10,853,784.00
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · nonDerivative · entry 3

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 5,666,822

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionCommon Stock 245,041 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · nonDerivative · entry 2

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 4,913,087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers give effect to such conversion. The B-1 Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 ConversionCommon Stock 4,668,046 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 4,668,046

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
August 26, 2020 Filed Aug 31, 2020 11:00 UTC YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 PurchaseCommon Stock 365,241 $4.25 $1,552,274.25
Disclosure

SEC source: 0001104659-20-100410 · tm2029838-2_4.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 793,635

F1 · kind: The reported securities were acquired by the Jack W. Schuler Living Trust.

F2 · balance_after: The reported securities consist of the 759,616 shares of common stock owned by the Jack W. Schuler Living Trust, the 21 shares of common stock owned by the Renate Schuler Living Trust, and the 33,998 shares of common stock owned by the Schuler Family Foundation, in each case immediately following reported transaction.

F3 · ownership.nature: Jack W. Schuler has an indirect pecuniary interest the reported securities through (i) the Jack W. Schuler Living Trust, as its trustee and beneficiary, (ii) the Renate Schuler Living Trust, as the spouse of its trustee and beneficiary, and (iii) the Schuler Family Foundation, as its president.

Read SEC document
July 01, 2020 Filed Jul 6, 2020 21:25 UTC Aspira Women's Health Inc. AWH · Entity 7871 PurchaseCommon Stock, par value $0.001 2,285,715 $3.50 $8,000,002.50
Disclosure

SEC source: 0000905148-20-000769 · form4.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 25,394,517

F1 · ownership.nature: These shares of common stock are directly held by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
June 26, 2020 Filed Jun 26, 2020 23:49 UTC SOLENO THERAPEUTICS INC SLNO · Entity 46432 PurchaseCommon Stock 2,424,242 $1.65 $3,999,999.30
Disclosure

SEC source: 0000899243-20-017808 · doc4.xml · nonDerivative · entry 2

SCHULER JACK W · CIK 0001021412 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,157,042

F1 · shares: The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on June 26, 2020.

F3 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President.

Read SEC document
June 26, 2020 Filed Jun 26, 2020 23:49 UTC SOLENO THERAPEUTICS INC SLNO · Entity 46432 PurchaseCommon Stock 5,151,517 $1.65 $8,500,003.05
Disclosure

SEC source: 0000899243-20-017808 · doc4.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 11,368,862

F1 · shares: The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on June 26, 2020.

F2 · ownership.nature: The shares are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee.

Read SEC document
June 22, 2020 Filed Nov 3, 2020 23:21 UTC BIODESIX INC BDSX · Entity 6053 Grant3% Convertible Debt due June 2021 · Derivative Not disclosed $0.00 $1,546,681.28
Disclosure

SEC source: 0001209191-20-056742 · doc4.xml · derivative · entry 13

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: Not disclosed

Underlying: Common Stock · 108,564 shares

Expires 2021-06-30

F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest.

F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest.

F2 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 15:30 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 95,492 $9.86 $941,551.12
Disclosure

SEC source: 0001628280-20-009594 · wf-form4_159242222607599.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 16,603,524

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.93 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
June 12, 2020 Filed Jun 16, 2020 15:32 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 134,080 $9.34 $1,252,307.20
Disclosure

SEC source: 0001628280-20-009503 · wf-form4_159233594118010.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 16,508,032

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.07 to $9.50, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
June 11, 2020 Filed Jun 15, 2020 15:35 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 129,000 $9.18 $1,184,220.00
Disclosure

SEC source: 0001628280-20-009429 · wf-form4_159224973794360.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 16,373,952

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.94 to $9.35, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
June 10, 2020 Filed Jun 12, 2020 15:28 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 100,000 $9.84 $984,000.00
Disclosure

SEC source: 0001628280-20-009333 · wf-form4_159199011999222.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 16,244,952

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.38 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
June 10, 2020 Filed Jun 13, 2020 00:32 UTC SOLENO THERAPEUTICS INC SLNO · Entity 46432 PurchaseCommon Stock 339,083 $1.97 $666,806.72
Disclosure

SEC source: 0000899243-20-016438 · doc4.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,071,883

F1 · price: This transaction was executed in multiple trades at prices ranging from $1.92 to $2.00. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate purchase price.

F2 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President.

Read SEC document
June 09, 2020 Filed Jun 11, 2020 15:36 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 180,955 $9.63 $1,742,596.65
Disclosure

SEC source: 0001628280-20-009259 · wf-form4_159190414579078.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 16,144,952

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.30 to $9.89, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
June 09, 2020 Filed Jun 12, 2020 01:32 UTC Aspira Women's Health Inc. VRML · Entity 7871 OtherWarrants (Right to buy) · Derivative 730,560 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0000905148-20-000694 · form4.xml · derivative · entry 2

SCHULER JACK W · CIK 0001021412 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 730,560 shares

Expires 2020-06-09

F1 · ownership.nature: These shares of common stock are directly held by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
June 09, 2020 Filed Jun 12, 2020 01:32 UTC Aspira Women's Health Inc. VRML · Entity 7871 OtherCommon Stock, par value $0.001 730,560 $1.80 $1,315,008.00
Disclosure

SEC source: 0000905148-20-000694 · form4.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 23,108,802

F1 · ownership.nature: These shares of common stock are directly held by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 14:49 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 1,100,000 $8.58 $9,438,000.00
Disclosure

SEC source: 0001628280-20-009157 · wf-form4_159172857289069.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 15,963,997

F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
June 05, 2020 Filed Oct 5, 2021 16:01 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 54,975 $9.08 $499,173.00
Disclosure

SEC source: 0001628280-21-019655 · wf-form4_163346401260762.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 54,975

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.97 to $9.22, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
May 14, 2020 Filed May 18, 2020 20:14 UTC QUIDEL CORP /DE/ QDEL · Entity 126712 Exercise / conversionRestricted Stock Units · Derivative 2,100 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-030271 · doc4.xml · derivative · entry 2

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date.

F4 · derivative.expiration_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date.

Read SEC document
May 14, 2020 Filed May 18, 2020 20:14 UTC QUIDEL CORP /DE/ QDEL · Entity 126712 Exercise / conversionCommon Stock 2,100 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-030271 · doc4.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,103,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4.

F2 · balance_after: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any.

Read SEC document
May 14, 2020 Filed Jul 16, 2021 17:18 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 29,577 $9.20 $272,108.40
Disclosure

SEC source: 0001628280-21-013967 · wf-form4_162647031767123.xml · nonDerivative · entry 2

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 16,633,101

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.97 to $9.40, inclusive. The reporting person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
May 13, 2020 Filed May 15, 2020 16:21 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 89,055 $9.46 $842,460.30
Disclosure

SEC source: 0001628280-20-007895 · wf-form4_158957404422286.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,863,997

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.09 to $9.60, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
May 12, 2020 Filed May 14, 2020 15:39 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 20,000 $9.92 $198,400.00
Disclosure

SEC source: 0001628280-20-007777 · wf-form4_158948516369338.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,774,942

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.85 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
May 12, 2020 Filed May 14, 2020 19:57 UTC QUIDEL CORP /DE/ QDEL · Entity 126712 GrantRestricted Stock Units (Equity Grant) · Derivative 1,040 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-029384 · doc4.xml · derivative · entry 3

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,040

Underlying: Common Stock · 1,040 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock.

F4 · derivative.exercise_date: The restricted stock units vest on May 12, 2021.

F4 · derivative.expiration_date: The restricted stock units vest on May 12, 2021.

Read SEC document
May 12, 2020 Filed May 14, 2020 19:57 UTC QUIDEL CORP /DE/ QDEL · Entity 126712 GrantRestricted Stock Units (Premium) · Derivative 82 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-029384 · doc4.xml · derivative · entry 2

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82

Underlying: Common Stock · 82 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock.

F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule.

F4 · derivative.exercise_date: The restricted stock units vest on May 12, 2021.

F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule.

F4 · derivative.expiration_date: The restricted stock units vest on May 12, 2021.

Read SEC document
May 12, 2020 Filed May 14, 2020 19:57 UTC QUIDEL CORP /DE/ QDEL · Entity 126712 GrantRestricted Stock Units (Converted) · Derivative 273 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-029384 · doc4.xml · derivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273

Underlying: Common Stock · 273 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock.

F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule.

F3 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 12, 2020.

F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule.

F3 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 12, 2020.

Read SEC document
May 11, 2020 Filed May 13, 2020 15:18 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 20,000 $9.99 $199,800.00
Disclosure

SEC source: 0001628280-20-007665 · wf-form4_158939746508444.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,754,942

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.96 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
May 07, 2020 Filed May 11, 2020 15:44 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 25,000 $9.87 $246,750.00
Disclosure

SEC source: 0001628280-20-007417 · wf-form4_158922627188967.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,734,942

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.66 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
May 06, 2020 Filed May 8, 2020 15:00 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 10,868 $10.00 $108,680.00
Disclosure

SEC source: 0001628280-20-007187 · wf-form4_158896443398136.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,709,942

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.98 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
May 05, 2020 Filed May 7, 2020 16:19 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 8,625 $10.00 $86,250.00
Disclosure

SEC source: 0001628280-20-006957 · wf-form4_158888272517909.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,699,074

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
May 04, 2020 Filed May 6, 2020 15:29 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 1,204 $9.98 $12,015.92
Disclosure

SEC source: 0001628280-20-006666 · wf-form4_158879334450372.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,690,449

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $9.99, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
May 01, 2020 Filed May 5, 2020 15:21 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 4,000 $10.03 $40,120.00
Disclosure

SEC source: 0001628280-20-006412 · wf-form4_158870650017962.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,689,245

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.96 to $10.36, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
April 24, 2020 Filed Apr 28, 2020 15:40 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 5,001 $10.00 $50,010.00
Disclosure

SEC source: 0001628280-20-005729 · wf-form4_158810281787536.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,685,245

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.99 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
April 23, 2020 Filed Apr 27, 2020 15:25 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 81,621 $9.90 $808,047.90
Disclosure

SEC source: 0001628280-20-005503 · wf-form4_158801550473372.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,680,244

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.68 to $10.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
April 22, 2020 Filed Apr 24, 2020 15:39 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 157,688 $9.47 $1,493,305.36
Disclosure

SEC source: 0001628280-20-005425 · wf-form4_158775712523702.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,598,623

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.11 to $9.67, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
April 21, 2020 Filed Apr 23, 2020 15:36 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 79,650 $9.01 $717,646.50
Disclosure

SEC source: 0001628280-20-005370 · wf-form4_158767054627987.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,440,935

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.77 to $9.35, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
April 20, 2020 Filed Apr 22, 2020 15:17 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 59,357 $9.40 $557,955.80
Disclosure

SEC source: 0001628280-20-005260 · wf-form4_158758303935067.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jack W. Schuler Living Trust

Disclosed balance after: 14,361,285

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.26 to $9.60, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
April 14, 2020 Filed Apr 14, 2020 20:11 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 GiftCommon Stock 1,100,000 $0.00 $0.00
Disclosure

SEC source: 0001628280-20-004973 · wf-form4_158690945159643.xml · nonDerivative · entry 1

SCHULER JACK W · CIK 0001021412 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Schuler Family Foundation

Disclosed balance after: 1,077,023

F1 · kind: The Schuler Family Foundation gifted 1,100,000 shares to a single unaffiliated charitable foundation. The Schuler Family Foundation disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.